Today, Nova Health, a leading company in the field of early cancer screening, has experienced major personnel changes. On December 31 (today), Nova Health announced that Mr. Zhu Yeqing has resigned as Chairman of the Board ("Chairman") and Chief Executive Officer of the Company ("CEO") on December 30, 2024 due to personal health reasons, effective from the same date ("Resignation").

At the same time, the announcement pointed out that the board of directors believes that Mr. Zhu Yeqing's management style and philosophy are significantly different from those of other members of the board of directors, and allowing Mr. Zhu Yeqing to continue to participate in the management of the company is not in the overall best interests of the company and its shareholders.

Given that Mr. Zhu Yeqing only resigned from the positions of Chairman and Chief Executive Officer, not the position of Executive Director, the board of directors has resolved to convene a special general meeting of shareholders to remove Mr. Zhu Yeqing from the position of Executive Director ("Proposed Removal"), effective from the date on which the special general meeting of shareholders passed the ordinary resolution approving the proposed removal.

The Board has resolved to appoint Mr. Yao Naxin, a non-executive director, to replace Mr. Zhu Yeqing as the Chairman and the authorized representative of the Company pursuant to Rule 3.05 of the Securities Listing Rules of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), effective from December 30, 2024.
The Board has resolved to appoint Mr. Yao Naxin to replace Mr. Zhu Yeqing as the Chairman of the Nomination Committee of the Company, effective from December 30, 2024.
The above means that on the same day, Zhu Yeqing is no longer the Chairman of the Board, CEO and Executive Director of NovaHealth. NovaHealth was founded in 2015 by three alumni of the School of Life Sciences of Peking University, Zhu Yeqing, Chen Yiyou and Lu Ning. Its main product, Changweiqing, as an early screening product for colorectal cancer, has always been used as a benchmark product for Exact Sciences Cologuard.
The company successfully landed on the Hong Kong Stock Exchange in February 2021. Since March 28, 2024, it has been suspended from trading on the Stock Exchange, and the suspension will continue until the resumption of trading guidelines are met. The board of directors emphasized that Zhu Yeqing’s resignation and proposed removal will not have a significant adverse impact on the group’s business operations.

https://mp.weixin.qq.com/